Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 55 entries
View as:

Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06375798 Org: User:
Start: 11/19/20 End: 11/19/26 Due: 11/19/27

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05086627 Org: User:
Start: 09/01/21 End: 08/20/24 Due: 08/20/25

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06010667 Org: User:
Start: 09/01/23 End: 08/01/26 Due: 08/01/27

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.

Phase: N/A Priority: Normal
NCT ID: NCT06973525 Org: User:
Start: 09/01/25 End: 05/31/32 Due: 05/31/33

Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06949098 Org: User:
Start: 05/15/25 End: 05/31/32 Due: 05/31/33

Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

Phase: N/A Priority: Normal
NCT ID: NCT06903871 Org: User:
Start: 04/01/25 End: 03/01/30 Due: 03/01/31

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03580395 Org: User:
Start: 06/01/17 End: 12/31/22 Due: 12/31/23

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03634059 Org: User:
Start: 08/15/18 End: 08/15/20 Due: 08/15/21

The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03022123 Org: User:
Start: 11/30/16 End: 03/31/18 Due: 03/31/19

Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study

Phase: N/A Priority: Normal
NCT ID: NCT06481449 Org: User:
Start: 01/01/00 End: 12/01/24 Due: 12/01/25

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03017404 Org: User:
Start: 05/31/15 End: 07/31/16 Due: 07/31/17

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Phase: N/A Priority: Normal
NCT ID: NCT06371482 Org: User:
Start: 06/01/23 End: 12/31/27 Due: 12/31/28

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05522491 Org: User:
Start: 09/01/22 End: 09/01/24 Due: 09/01/25

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Phase: N/A Priority: Normal
NCT ID: NCT04067102 Org: User:
Start: 05/10/19 End: 05/31/26 Due: 05/31/27

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Phase: N/A Priority: Normal
NCT ID: NCT07019272 Org: User:
Start: 06/30/25 End: 10/31/30 Due: 10/31/31

Minimally Residual of Esophageal Cancer 001

Phase: N/A Priority: Normal
NCT ID: NCT05952661 Org: User:
Start: 02/22/23 End: 12/31/27 Due: 12/31/28

A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06323265 Org: User:
Start: 03/26/24 End: 04/01/26 Due: 04/01/27

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05578053 Org: User:
Start: 10/26/22 End: 12/01/26 Due: 12/01/27

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06210971 Org: User:
Start: 02/01/24 End: 07/01/28 Due: 07/01/29

Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06851819 Org: User:
Start: 03/01/25 End: 06/30/29 Due: 06/30/30

A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC

Phase: N/A Priority: Normal
NCT ID: NCT04286958 Org: User:
Start: 04/22/20 End: 03/01/23 Due: 03/01/24

Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Phase: N/A Priority: Normal
NCT ID: NCT06420908 Org: User:
Start: 05/30/24 End: 05/30/27 Due: 05/30/28

Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06103890 Org: User:
Start: 05/22/23 End: 07/31/25 Due: 07/31/26

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Phase: N/A Priority: Normal
NCT ID: NCT06056115 Org: User:
Start: 05/01/23 End: 12/12/26 Due: 12/12/27

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase: N/A Priority: Normal
NCT ID: NCT06107673 Org: User:
Start: 09/30/23 End: 12/01/25 Due: 12/01/26